Abstract 336P
Background
CIPN is a dose-limiting and disabling side effect of oxaliplatin and/or paclitaxel. We prospectively evaluated the efficacy of methylcobalamin administered intravenously for CIPN.
Methods
Thirty patients with gastrointestinal cancer who were receiving oxaliplatin and/or paclitaxel and had peripheral neuropathy of CTCAE ≥ 2 were enrolled to the trial. Each patient recieving chemotherapy containing oxaliplatin and/or paclitaxel and devoloping CIPN>Grade 1 was assessed CIPN on day 3 and (T1) a day before the next cycle (T2) with Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT) for two cycles. Methylcobalamin intramuscularly was used for the first cycle and intravenously for the second cycle in the first 15 patients. Injection order was reversed in the latter 15 patients. Methylcobalamin 5 mg/d was given from day 3 to a day before the next cycle. The primary end point was a change of CIPNAT score between T1 and T2.
Results
Thirty patients were enrolled and completed the trial. Median age was 62 (range, 31- 76), male/female was 20/10. Most primary sites were gastric cancer (n=13), colorectal cancer (n=12). Most regimens were paclitaxel/oxaliplatin/5-FU (n=13), FOLFOXIRI (n=11), FOLFOX (n=3), paclitaxel/5-FU (n=2), nab-paclitaxel (n=1). The mean number of cycles of chemotherapy before the start of methylcobalamin injection was 6 (1-12). The total CIPNAT scores (mean±SD) were 148.90±56.09 for T1, 41.40±37.52 for T2 in the intravenous cycle, 158.90±57.02 for T1, 120.20±56.02 for T2 in the intramuscular cycle. A decline in CIPNAT score (mean±SD) between T1 and T2 was 107.50±42.04 in the intravenous cycle, and 38.70±30.33 in the intramuscular cycle (Z=5.715, P<0.001). No significant drug and injection-related side effects were observed in both groups.
Conclusions
Intravenous methylcobalamin is more effective than intramuscular injection in oxaliplatin and/or paclitaxel-induced peripheral neurotoxicity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rongbo Lin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
34P - Clinical significance of neoadjuvant dose-dense chemotherapy for II and III stage breast cancer: A meta-analysis of published studies
Presenter: Meng chen Liu
Session: e-Poster Display Session
35P - Pathological response to weekly nabpaclitaxel and carboplatin followed by anthracycline regimen in triple negative breast cancer
Presenter: Goteti Sharat Chandra
Session: e-Poster Display Session
36P - Survival in patients with contralateral breast cancer
Presenter: Sergey Kamishov
Session: e-Poster Display Session
37P - Correlation between haematological toxicity with quality of life in breast cancer patients after first-cycle chemotherapy
Presenter: felix Wijovi
Session: e-Poster Display Session
38P - Evaluation of the prognostic value of innate immunity-related biomarkers in early breast cancer (BC)
Presenter: Veronica Martini
Session: e-Poster Display Session
39P - CSF-1R inhibitor (C019199) enhances antitumor effect in combination with anti-PD-1 therapy on murine breast cancer models
Presenter: Jiani Zheng
Session: e-Poster Display Session
40P - Molecular subtypes and imaging phenotypes of breast cancer: MRI
Presenter: Yulduz Khatamovna
Session: e-Poster Display Session
41P - Mir-223 overexpression is associated with increased expression of EGFR and worse prognosis in Indonesian TNBC patients
Presenter: Ibnu Purwanto
Session: e-Poster Display Session
42P - Impact of germline mutations on breast cancer prognosis in Kazakh population
Presenter: Dilyara Kaidarova
Session: e-Poster Display Session
50P - Efficacy and safety analysis of pyrotinib in lapatinib resistant HER2-positive metastatic breast cancer: A retrospective study
Presenter: Yijia Hua
Session: e-Poster Display Session